D
David R. Gandara
Researcher at University of California, Davis
Publications - 725
Citations - 45633
David R. Gandara is an academic researcher from University of California, Davis. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 84, co-authored 685 publications receiving 40321 citations. Previous affiliations of David R. Gandara include National Institutes of Health & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Pharmacodynamic separation (PDS) of pemetrexed (Pem) and erlotinib (Erl) in patients (pts) with advanced, EGFR wild-type (wt) Non-Small Cell Lung Cancer (NSCLC): A randomized phase II trial.
Tianhong Li,Bilal Piperdi,William V. Walsh,Mimi Y. Kim,Laurel A. Beckett,Huiyu Wen,Kaili Zhou,Rasim Gucalp,Missak Haigentz,Venu Bathini,Srikanth Gajavelli,Meera Sreedhara,Primo N. Lara,David R. Gandara,Roman Perez-Soler +14 more
TL;DR: The efficacy analysis restricted to those pts with confirmed EGFR wt NSCLC, and the parent study was designed to detect an increase in median progression-free survival (mPFS) by 50%, i.e., a hazard ratio (HR) of 1.8044.
Journal Article
Divergent activity of afatinib (afat) and cetuximab (cet) in patient-derived xenograft (pdx) models of acquired erlotinib resistance.
Philip C. Mack,Neal Goodwin,W. S. Holland,Karen Kelly,Tianhong Li,Primo N. Lara,David R. Gandara +6 more
TL;DR: Heavey et al. as discussed by the authors performed broad proteomic analysis of NSCLC cell lines treated with MEK inhibitor BAY86-9766 and found that the PI3K/Akt pathway activation predicts for resistance to MEK inhibition.
Journal ArticleDOI
Inhibition of the AKT pathway with genistein combined polysaccharide (GCP) plus external beam radiation therapy (EBRT) in a prostate cancer (CaP) xenograft
W. S. Holland,D. Shih,R. Harse,Srinivasan Vijayakumar,Robert M. Hackman,David R. Gandara,R. W. Devere White,Paul H. Gumerlock +7 more
TL;DR: This data indicates that activation of the AKT pathway of survival has been identified in patients with primary CaP who will fail biochemically within 5 years following EBRT.
Journal ArticleDOI
Chemotherapy of metastatic testicular cancer: current status and future prospects
TL;DR: Clinical research in this patient population has focused primarily on methods of intensifying treatment, such as alternating non-cross-resistant drug combinations, increasing the dose intensity of cisplatin, and investigating new active agents such as ifosfamide.